- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05796505
Ta tak i vaksineaksept i kreftmiljøer gjennom samfunnsengasjement
The objective of this study is to identify a set of interventions that are effective in improving preventive healthcare engagement, including vaccination and chronic disease prevention, among incarcerated individuals and correctional staff in the Pennsylvania prison system.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Aim 1: Identify promising strategies and implementation approaches for respiratory preventive health engagement, including vaccination, among correctional staff and formerly incarcerated individuals from high-performing correctional systems.
Aim 2: Select community-endorsed prevention strategies for a statewide correctional system.
Aim 3: Test the effectiveness of strategies to improve respiratory preventive health engagement using rapid-cycle, cluster randomized trials and related evaluative activities, as applicable.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Lisa B Puglisi, MD
- Telefonnummer: 475-306-1023
- E-post: Lisa.puglisi@yale.edu
Studiesteder
-
-
Pennsylvania
-
Schwenksville, Pennsylvania, Forente stater, 19473
- Rekruttering
- Pennsylvannia Department of Corrections
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- All incarcerated people in the Pennsylvania DOC are included in the study population for these low risk interventions. In this each individual intervention, inclusion criteria will be based on where incarcerated people are housed and therefore what intervention they will be exposed to.
Exclusion Criteria:
- Exclusion criteria will likely include severe physical or mental illness as these individuals are often incarcerated in special units which will not be included in the study (i.e. medical units).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Treatment as usual
Participants receive standard interventions currently in use (treatment as usual). |
|
|
Eksperimentell: ADVANCE Steering Committee chosen interventions
Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination. |
Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
COVID-19 vaccine acceptance rate
Tidsramme: up to 12 weeks post intervention
|
Acceptance rate amongst incarcerated people and correctional staff assessed as the number of participants that receive a COVID-19 vaccine dose or complete the COVID-19 vaccine series by electronic health record (EHR) or self report inclusive of boosters. |
up to 12 weeks post intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Respiratory infections rate
Tidsramme: up to 12 weeks post intervention
|
Number of participants with respiratory infections by EHR or self report. |
up to 12 weeks post intervention
|
|
Hospitalization Rate
Tidsramme: up to 12 weeks post intervention
|
Total number of new admissions for COVID-19 infections by EHR or self report. |
up to 12 weeks post intervention
|
|
Deaths
Tidsramme: up to 12 weeks post intervention
|
Number of deaths from COVID-19 infections by EHR |
up to 12 weeks post intervention
|
|
Influenza vaccine acceptance rate
Tidsramme: up to 12 weeks post intervention
|
Vaccine acceptance rate assessed by number of vaccines administered/total number fully vaccinated at start of the intervention |
up to 12 weeks post intervention
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Lisa B Puglisi, MD, Yale University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2000035026
- 1R01MD016853-01A1 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .